Technician

Commonwealth Fusion Energy secures $1 billion to revolutionize clean power generation. Key points. * Commonwealth Fusion Energy raises $1 billion to advance fusion technology. * The company aims to commercialize fusion energy by the early 2030s. * CFS collaborates with MIT to develop the SPARC fusion demonstration machine. * Fusion energy promises clean power using hydrogen without carbon emissions. Commonwealth Fusion Energy (CFS) has made headlines with its recent announcement of raising an impressive $1 billion in equity funding. This financing round is considered the largest in the fusion industry since their $1.8 billion round back in 2021, and it highlights the growing investor confidence in the commercialization of fusion energy technology. The total capital raised by CFS now stands at $4 billion, which accounts for approximately 30% of the total capital in the fusion energy sector to date. Fusion energy, often referred to as the "Holy Grail" of clean energy production, involves the process of combining two atoms to create a single atom, releasing significant amounts of energy in the process. This method has the potential to harness power from hydrogen - the most plentiful element in the universe - while eliminating the carbon emissions typically associated with fossil-fuel energy sources and avoiding the highly radioactive waste produced by nuclear fission. The path to large-scale fusion energy generation has been challenging, primarily due to the requirement of achieving extremely high temperatures and pressure. CFS, which was spun out of the Massachusetts Institute of Technology (MIT) in 2018, is on a mission to develop the world's first net-energy positive fusion device that generates more energy than it consumes. The organization is utilizing a tokamak design that utilizes high-temperature superconducting magnets arranged in a donut shape to confine and manage plasma, thus creating the essential conditions for fusion. Currently, CFS is collaborating with MIT's Plasma Science and Fusion Center to construct SPARC, which is a precursor to their foundational commercial plant, ARC. They anticipate that the ARC plant will be the first grid-scale fusion power plant globally. Furthermore, CFS has announced power purchase agreements (PPAs) with major companies such as Google and Eni, which will cover more than half of the energy that the ARC plant is expected to produce. The infusion of new capital will allow CFS to expedite its progress toward commercialization, focusing on completing the assembly of the SPARC fusion demonstration machine and advancing the development of the ARC power station located in Chesterfield County, Virginia. Bob Mumgaard, the CEO and Co-founder of CFS, expressed confidence in their vision, stating that they are transforming what was once deemed impossible into an inevitable reality. He predicts that by the 2030s, commercial fusion will be operational on the grid, further emphasizing their commitment to sustainability and the positive impact of unlocking commercial fusion energy at a civilizational level. July 31, 2026 at 10:30 PM Devens, United States

When will fusion power startup Commonwealth Fusion Systems go public? 3 3 minutes read Commonwealth Fusion Systems (CFS) is the best funded fusion power startup, having raised $4 billion from investors over the last seven years, including the $1 billion the company has raised now. Now, developments at CFS, plus rumblings from industry sources TechCrunch has spoken with in recent months, suggest that the startup might go public in the next two or three years. One of those developments was the appointment of Lorence Kim as CFS's new Chief Financial Officer this week. Kim's previous stint as a CFO was at Moderna, a biotech which specializes in mRNA therapies, which he joined in 2014 and subsequently helped take public in December 2018. He stuck around another year-and-a-half before returning to biotech investing. Kim said he sees "something very familiar" in CFS. "Fusion today is where mRNA was a decade ago: scientifically real, commercially yet-to-be-proven, and closer than the consensus thinks," he wrote in a LinkedIn post. The choice might seem unusual, but Kim isn't the first fusion executive to come with a background in the biotech world: Eric Lander, who helped lead the Human Genome Project, co-founded Pacific Fusion and now serves as its CEO. "Lorence offers the unique experience of bringing to the world a completely novel, mission-driven product that sits at the intersection of breakthrough deep science, geopolitical urgency, and deployment at scale and speed," Christine Dunn, head of external communications at CFS, told TechCrunch. She added that Kim said his arrival doesn't necessarily mean that IPO preparations are underway. Moderna took four-and-a-half years to IPO after Kim joined. But given the progress at CFS (and Kim's recent arrival, protestations notwithstanding), the startup is likely to go public sooner than that. A few points support its theory of a shorter timeline. First, Moderna develops therapies for human diseases that don't hit the market until they're approved by the FDA, which requires data from lengthy and costly clinical trials. That timeline is driven by the fact that human lives are at stake. With fusion, however, the potential of deadly errors is lower. Fusion reactors fizzle out instead of melting down, so they're safer than fission reactors. Recognizing that, federal regulators have given the fusion industry guidelines that are distinct from the fission industry. In that sense, CFS has greater control over its destiny. Second, CFS is making steady progress on Sparc, its demonstration reactor. Years ago, it had hoped to get the device up and running by 2025, and it is now targeting a launch later this year. Still, a large, first-of-a-kind project can avoid some delays, and CFS has managed to keep them from becoming excessive. The company hopes that by next year, Sparc will achieve scientific breakeven - when a fusion reaction produces more energy than was required to start it. So far, only one experiment has achieved scientific breakeven, so reaching that milestone would help CFS show investors that it is making steady progress toward commercialization. Lastly, CFS has started work on its commercial scale power plant, Arc. It has selected a site in Chesterfield County, Virginia, and has started receiving the necessary permits. CFS hopes to have Arc up and running in the early 2030s. If CFS goes public in the coming years, it will still have several years of heavy expenditures ahead. From that perspective, hiring Kim may prove a wise move, considering he oversaw Moderna during its early years as a public company, when it was losing money until the COVID-19 pandemic delivered an unexpected windfall. The current AI data center boom is a similar sort of black swan event, so it makes sense that CFS will want to strike before investor appetite wanes. One fusion company, General Fusion, went public via a SPAC deal earlier this month, and another, TAE Technologies, will do so by merging with Trump Media and Technology Group. Tech companies today are buying electricity at seemingly any cost. CFS knows this, having already sold half the output of its first power plant to Google. But IPO windows don't last forever, and CFS won't want to let this opportunity pass it by. When you purchase through links in its articles, Real Hacker may earn a small commission. This doesn't affect its editorial independence.